Advertisement

Efficacy and Safety of Intragastric Balloon Placements in 1600 Case, an Experience from the Middle East

  • Mohamed AbeidEmail author
  • Tarek Kaddah
  • Nahla A. Zaitoun
  • Mohd Amer Alsamman
Original Contributions

Abstract

Background and Purpose

Intragastric balloons are used as a treatment for obesity. Much of the data collected on balloons had been in the context of clinical trials in academic medical centers or as a bridge to bariatric surgery in obesity centers. The aim of this study was to investigate the efficacy and safety of balloon treatment in private practice.

Study Design

This is an interventional study.

Subjects

The study included 1600 patients.

Place

The study was conducted at the ElKatib Hospital.

Method

This was a retrospective analysis of 6-month weight loss data and balloon-related complications of patients referred to a private center for obesity treatment.

Assessment

The assessment was carried out by obtaining full patients’ history (personal history, present illness, and previous drug history and operations). Laboratory work was done in the form of CBC, blood sugar, and viral markers. Bioenterics Intragastric Balloon (BIB) silicone balloon was used, filled with saline plus methylene blue dye with a volume ranging from 400 to 700 ml. The gained measures were analyzed by using SPSS program, and paired t test and chi-square test were used to compare between groups.

Results

A total of 1600 patients were included (368 male (23%) and 1232 female (77%)) with mean age 34.1 ± 10.354, mean body weight 112.45 ± 26.24, and mean body mass index (BMI) 40.32 ± 8.17. There were 46 patients younger than 18 years and 12 patients older than 60 years. There were 109 patients with a BMI ranging from 25 to < 35 and 737 patients with a BMI ≥ 40 kg/m2. A total of 1567 patients who attended weight consultation had a mean weight loss 17.35 ± 11.07 from intragastric balloon implantation. Thirty-three patients from the total sample were not weighted after the removal of the balloon (dropped out). Percentage excess weight loss (% EWL) = 100% × (baseline absolute weight (AW)−last weight)/(baseline AW−initial body weight (IBW)) was found, and weight loss of more than 10% was considered significant. About 49.3% of patients showed significant weight loss > 10%, 24.7% of patients showed weight loss > 20%, while 26% of patients showed no significant weight loss < 10%.

Conclusion

Intragastric balloons on their own, with an intensive lifestyle program and supportive consultations, resulted in safe and short-term substantial weight loss, and may fill the therapeutic gap between pharmacotherapy and surgery.

Keywords

Intragastric balloon  BMI BIB 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

A Statement of Informed Consent

Informed consent was obtained from all individual participants included in the study.

A Statement of Human Rights

The study has been approved by the ministry of health and the hospital ethics committee and has been performed in accordance with the ethical standards.

References

  1. 1.
    World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity, Geneva, Report no.: WHO/NUT/NCD/98.1 Geneva: WHO; 1998.Google Scholar
  2. 2.
    Isidro L, Cordido F. Approved and off-label use of obesity medications, and potential new pharmacologic treatment options. Pharmaceuticals. 2010;3:125–45.CrossRefGoogle Scholar
  3. 3.
    Swidnicka-Siergiejko A, Wróblewski E, Dabrowski A. Endoscopic treatment of obesity. Can J Gastroenterol. 2011;25(11):627–33.CrossRefGoogle Scholar
  4. 4.
    Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18:841–6.CrossRefGoogle Scholar
  5. 5.
    de Moura EG, Orso IR, Martins BC, et al. Improvement of insulin resistance and reduction of cardiovascular risk among obese patients with type 2 diabetes with the duodenojejunal bypass liner. Obes Surg. 2011;21:941–7.CrossRefGoogle Scholar
  6. 6.
    Melissas J, Mouzas J, Filis D, et al. The intragastric balloon – smoothing the path to bariatric surgery. Obes Surg. 2006;16:897–902.CrossRefGoogle Scholar
  7. 7.
    Mathus-Vliegen Elisabeth MH, Alders PRH, Chuttani R, et al. Intragastric balloons in a private practice setting. Gastrointest Endosc. 2015;47:302–7.Google Scholar
  8. 8.
    Elia PP, Freire A, Silva GC, Teixeira N, Teixeira JM, Feldman G, Moraes CE, Wrobel D and Carvalho G. Efficacy and safety of intragastric balloon for obesity and pre- obese patients: a Brazilian experience gastrointestinal endoscopy. 2010;71(5).Google Scholar
  9. 9.
    Negrin Dastis S, François E, Deviere J, et al. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Gastrointest Endosc. 2009;41:575–80.Google Scholar
  10. 10.
    Almeida LS. Results of 700 cases of intragastric balloon. Gastrointest Endosc. 2015;81(5S):AB459.CrossRefGoogle Scholar
  11. 11.
    Uyak D, Galle V. Endoscopic treatment of obesity using a gastric balloon (B.I.B) study data of 101 patients with a BMI of 27 or more with gastric balloon implantations. Gastrointest Endosc. 2010;71(5)Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Faculty of MedicineCairo UniversityCairoEgypt
  2. 2.Warren Alpert School of MedicineBrown UniversityProvidenceUSA

Personalised recommendations